Literature DB >> 17415337

Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review.

Silvai Iannello1, Paolina Milazzo, Fabio Bordonaro, Francesco Belfiore.   

Abstract

Hypertrophic scars and keloids are 2 forms of excessive cutaneous scarring that occur in predisposed individuals. The healing process varies greatly among patients, and the risk of a bad scar evolution is unpredictable. Keloids create disfiguring scars with associated erythema and pain or pruritus or restricted range of motion, and are a major cause of morbidity. A fortuitous observation was made by the first author of this study who, at age 54, developed an erythematous and painful postsurgical abdominal keloid scar after undergoing left colectomy for colon adenocarcinoma. Four months later, after treatment with low-dose enalapril (10 mg, once a day) for mild arterial hypertension, her keloid scar rapidly improved and she eventually made a complete recovery. second case involved a 70-year-old female with diabetes who was affected by a long-standing postsurgical abdominal keloid scar of 2 years' duration. She was intentionally treated with the same low dose of enalapril, and, after 6 months of therapy, the bad scar showed marked improvement. We conducted an exhaustive search of the literature pertaining to the wound healing process, specifically to determine whether angiotensin-converting enzyme (ACE) inhibitors have a healing effect on wounds. ACE inhibitors are known to induce reduction of left ventricular collagen content and to attenuate remodeling during the postinfarctual period (thus improving ventricular function), and they have been shown to exert a pulmonary antifibrotic effect. After conducting this literature search, it became apparent that no data on cutaneous scars and ACE inhibitors are available. During the posttraumatic or postoperative stage, it is useful to achieve the best possible aesthetic results and to decrease the risk of a disfiguring keloid scar, thereby avoiding revision surgery; to this purpose, an early treatment with a low dose of enalapril is a possible solution, even if further confirmatory observations are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17415337      PMCID: PMC1868346     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  47 in total

1.  Treating keloids with carbon dioxide lasers.

Authors:  B Driscoll
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-09

2.  Differences in collagen production between normal and keloid-derived fibroblasts in serum-media co-culture with keloid-derived keratinocytes.

Authors:  Toan-Thang Phan; Ivor J Lim; Boon-Huat Bay; Robert Qi; Hung T Huynh; Seng-Teik Lee; Michael T Longaker
Journal:  J Dermatol Sci       Date:  2002-05       Impact factor: 4.563

3.  Opposite effects of amlodipine and enalapril on infarct collagen and remodelling during healing after reperfused myocardial infarction.

Authors:  B I Jugdutt; S Musat-Marcu
Journal:  Can J Cardiol       Date:  2000-05       Impact factor: 5.223

Review 4.  International clinical recommendations on scar management.

Authors:  Thomas A Mustoe; Rodney D Cooter; Michael H Gold; F D Richard Hobbs; Albert-Adrien Ramelet; Peter G Shakespeare; Maurizio Stella; Luc Téot; Fiona M Wood; Ulrich E Ziegler
Journal:  Plast Reconstr Surg       Date:  2002-08       Impact factor: 4.730

Review 5.  New therapies for the management of keloids.

Authors:  Varee N Poochareon; Brian Berman
Journal:  J Craniofac Surg       Date:  2003-09       Impact factor: 1.046

6.  Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy.

Authors:  Raj Ragoowansi; Paul G S Cornes; Anthony L Moss; John P Glees
Journal:  Plast Reconstr Surg       Date:  2003-05       Impact factor: 4.730

7.  Angiotensin II and the fibroproliferative response to acute lung injury.

Authors:  Richard P Marshall; Peter Gohlke; Rachel C Chambers; David C Howell; Steve E Bottoms; Thomas Unger; Robin J McAnulty; Geoffrey J Laurent
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-16       Impact factor: 5.464

8.  Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months.

Authors:  Rei Ogawa; Kiyoshi Mitsuhashi; Hiko Hyakusoku; Tuguhiro Miyashita
Journal:  Plast Reconstr Surg       Date:  2003-02       Impact factor: 4.730

9.  Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.

Authors:  Ardeshir Bayat; Oliver Bock; Uli Mrowietz; William E R Ollier; Mark W J Ferguson
Journal:  Plast Reconstr Surg       Date:  2003-02       Impact factor: 4.730

Review 10.  TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy.

Authors:  W Liu; D R Wang; Y L Cao
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

View more
  18 in total

Review 1.  Managing keloid scars: From radiation therapy to actual and potential drug deliveries.

Authors:  Chenyu Huang; Longwei Liu; Zhifeng You; Yanan Du; Rei Ogawa
Journal:  Int Wound J       Date:  2019-03-12       Impact factor: 3.315

2.  Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction.

Authors:  Tosan Ehanire; Licheng Ren; Jennifer Bond; Manuel Medina; George Li; Latif Bashirov; Lei Chen; George Kokosis; Mohamed Ibrahim; Angelica Selim; Gerard C Blobe; Howard Levinson
Journal:  J Mol Med (Berl)       Date:  2014-10-28       Impact factor: 4.599

3.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

4.  Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-β-activated kinase 1 (TAK1) pathways in mice.

Authors:  Wei-Qiang Tan; Qing-Qing Fang; Xiao Z Shen; Jorge F Giani; Tuantuan V Zhao; Peng Shi; Li-Yun Zhang; Zakir Khan; You Li; Liang Li; Ji-Hua Xu; Ellen A Bernstein; Kenneth E Bernstein
Journal:  Br J Pharmacol       Date:  2018-10-08       Impact factor: 8.739

5.  CASE REPORT Total Management of a Severe Case of Systemic Keloids Associated With High Blood Pressure (Hypertension): Clinical Symptoms of Keloids May Be Aggravated by Hypertension.

Authors:  Rei Ogawa; Juri Arima; Shimpei Ono; Hiko Hyakusoku
Journal:  Eplasty       Date:  2013-06-03

Review 6.  Keloids: a review of therapeutic management.

Authors:  Samuel F Ekstein; Saranya P Wyles; Steven L Moran; Alexander Meves
Journal:  Int J Dermatol       Date:  2020-09-09       Impact factor: 3.204

7.  Modulation of angiotensin II signaling in the prevention of fibrosis.

Authors:  Amanda M Murphy; Alison L Wong; Michael Bezuhly
Journal:  Fibrogenesis Tissue Repair       Date:  2015-04-23

8.  Embryonic Stem Cell-Like Population in Dupuytren's Disease Expresses Components of the Renin-Angiotensin System.

Authors:  Nicholas On; Sabrina P Koh; Helen D Brasch; Jonathan C Dunne; James R Armstrong; Swee T Tan; Tinte Itinteang
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-24

9.  Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-β1 pathways.

Authors:  Qing-Qing Fang; Xiao-Feng Wang; Wan-Yi Zhao; Shi-Li Ding; Bang-Hui Shi; Ying Xia; Hu Yang; Li-Hong Wu; Cai-Yun Li; Wei-Qiang Tan
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

10.  Expression and Localization of Cathepsins B, D, and G in Dupuytren's Disease.

Authors:  Kirin Tan; Helen D Brasch; Bede van Schaijik; James R Armstrong; Reginald W Marsh; Paul F Davis; Swee T Tan; Tinte Itinteang
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.